Integrated analyses of melanoma-T cell interactions; relevance for immunotherapy
Completed
- Conditions
- skin cancer100276651004090010035023
- Registration Number
- NL-OMON29970
- Lead Sponsor
- KI-AV
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 40
Inclusion Criteria
Metastatic melanoma; (sub)cutaneous metastases
Exclusion Criteria
Hemophilia en other blood coagulation disorders
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>The presence of melanoma-reactive T lymphocytes will be determined in the tumor<br /><br>tissue and in the blood of each patient. These T lymphocytes will subsequently<br /><br>be tested for the ability to lyse melanoma cells in the metastasis and/or<br /><br>melanocytes in the skin, using the skin/tumor explant system. The analyses in<br /><br>this system also incorporate the influence of the tissue microenvironment on<br /><br>the T cell functionality. </p><br>
- Secondary Outcome Measures
Name Time Method <p>Our ex vivo in situ tumor and skin explant system is the first to integrate the<br /><br>multidimensionality of human tumor-host interactions, and can therefore predict<br /><br>the efficacy of these interactions in vivo more accurately than in vitro assays<br /><br>based on rather artificial interactions between cells in suspension.<br /><br><br /><br>This study provides insight in the defects in individual patients that cause<br /><br>failure of tumor regression by immunotherapy and may lead to novel strategies<br /><br>to overcome these defects and improved immunotherapy of melanoma in the future.</p><br>